

Interview Summary	Application No. 10/036,768	Applicant(s) ACKERMAN ET AL.	
	Examiner Jennifer Kim	Art Unit 1617	

All participants (applicant, applicant's representative, PTO personnel):

(1) Jennifer Kim. (3) _____.

(2) Mr. David Johnson. (4) _____.

Date of Interview: 23 April 2004.

Type: a) ☒ Telephonic b) ☐ Video Conference
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☒ No.
If Yes, brief description: _____.

Claim(s) discussed: Pending claims.

Identification of prior art discussed: Budowsky et al.


Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.


 Examiner's signature, if required 4/23/04

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Mr. Johnson the difference between prior art cited by the Examiner and Applicants invention that mononuclear cells of the immunosuppressive patients are treated with aziridino-containing compound first and re-distributed to the patient by administering treated blood cells. Mr. Johnson also discusses that newly added claim 36 is drawn to nonviricidal amount of aziridino-containing compound whereas the prior art requires viricidal amount of aziridino-containing compound.